Kwality Pharmaceuticals Ltd Stock Hits All-Time High at Rs.1410

Record-Breaking Price Movement

On 13 Feb 2026, Kwality Pharmaceuticals Ltd touched an intraday high of Rs.1410, representing a 3.52% increase from its previous levels. Despite a slight retracement after two consecutive days of gains, the stock closed with a positive day change of 1.49%, outperforming the Sensex which declined by 0.91% on the same day. The stock’s trading range for the day was between Rs.1321.1 and Rs.1410, demonstrating notable volatility but an overall upward trajectory.

The company’s share price currently trades above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a strong bullish trend and investor confidence in its medium to long-term prospects.

Exceptional Relative Performance Against Benchmarks

Kwality Pharmaceuticals Ltd has delivered outstanding returns relative to the broader market indices. Over the past week, the stock surged 19.41% compared to the Sensex’s decline of 0.80%. The momentum continued over the month with a 30.64% gain versus the Sensex’s 0.85% fall. Over three months, the stock appreciated by 42.30%, significantly outperforming the Sensex’s 1.85% decline.

Most notably, the stock has generated a 76.99% return over the last year, dwarfing the Sensex’s 8.90% gain. Year-to-date performance stands at 24.72%, while the Sensex has fallen by 2.71%. Over a three-year horizon, Kwality Pharmaceuticals Ltd has delivered a staggering 297.10% return, vastly outperforming the Sensex’s 37.20%. The five-year performance is even more remarkable, with a 2368.39% increase compared to the Sensex’s 60.86% rise.

Financial Strength and Profitability Metrics

Kwality Pharmaceuticals Ltd’s financial metrics underpin its strong market performance. The company boasts a low Debt to EBITDA ratio of 1.13 times, indicating a solid ability to service its debt obligations. This financial prudence has supported consistent profitability, with net profit growth of 87.79% reported in the December 2025 quarter.

The company has declared positive results for eight consecutive quarters, reflecting sustained operational efficiency and market demand. Its Return on Capital Employed (ROCE) for the half-year period stands at an impressive 19.03%, while the inventory turnover ratio is high at 5.04 times, signalling effective inventory management.

Operating profit to interest coverage ratio for the quarter is also robust at 12.08 times, highlighting strong earnings relative to interest expenses and reinforcing the company’s financial stability.

Long-Term Consistency and Sector Positioning

Kwality Pharmaceuticals Ltd has consistently outperformed the BSE500 index in each of the last three annual periods, demonstrating resilience and growth in a competitive sector. The company’s Mojo Score of 77.0 and an upgraded Mojo Grade to Buy from Hold as of 29 Jan 2026 further validate its strong market standing and favourable outlook within the Pharmaceuticals & Biotechnology industry.

Its market capitalisation grade is rated 4, reflecting a mid-sized market cap with potential for further recognition. The stock’s ability to maintain upward momentum despite sector headwinds is noteworthy, even as it slightly underperformed the sector by 0.52% on the day of the all-time high.

Valuation and Growth Considerations

While the company’s operating profit has grown at an annual rate of 18.44% over the past five years, the valuation metrics suggest a premium positioning. The ROCE of 20.1 and an enterprise value to capital employed ratio of 4.1 indicate an expensive valuation relative to capital utilisation.

However, the stock trades at a discount compared to its peers’ average historical valuations, offering a relative value proposition. The price-to-earnings-to-growth (PEG) ratio stands at 0.4, reflecting a favourable balance between price and earnings growth over the past year, where profits rose by 64.5% alongside the 76.99% stock return.

Despite the company’s size and strong fundamentals, domestic mutual funds currently hold no stake in Kwality Pharmaceuticals Ltd. This absence may reflect cautious positioning by institutional investors, possibly due to valuation or business model considerations.

Summary of the Journey to the All-Time High

Kwality Pharmaceuticals Ltd’s ascent to Rs.1410 marks a significant milestone in its market journey. The stock’s performance over the last decade, while showing no recorded returns in the 10-year window, has been exceptional in the shorter and medium terms, particularly over the last five years with a 2368.39% gain.

This trajectory has been supported by strong quarterly results, prudent financial management, and consistent operational execution. The company’s ability to maintain upward momentum across multiple moving averages and outperform key indices highlights its resilience and market appeal.

While valuation metrics suggest a premium, the company’s strong fundamentals and consistent profit growth underpin the sustainability of its current market position. The milestone of reaching an all-time high is a testament to Kwality Pharmaceuticals Ltd’s robust business model and effective capital utilisation within the Pharmaceuticals & Biotechnology sector.

Closing Observations

Kwality Pharmaceuticals Ltd’s record share price of Rs.1410 reflects a culmination of strong financial results, consistent growth, and favourable market dynamics. The company’s performance metrics, including net profit growth, ROCE, and operating profit to interest coverage, demonstrate a well-managed enterprise with solid fundamentals.

Despite some valuation considerations and the absence of domestic mutual fund holdings, the stock’s sustained outperformance relative to the Sensex and sector benchmarks confirms its status as a leading player in its industry segment. The all-time high price milestone is a significant achievement that highlights the company’s successful journey and current market strength.

Unlock special upgrade rates for a limited period. Start Saving Now →